DOCSLIB.ORG

Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343 Supplementary material BMJ Open Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343 Albuterol Adrenergics 930021 alfuzosin Adrenergics 919986 apraclonidine Adrenergics 1111220 arformoterol Adrenergics 1314002 Atenolol Adrenergics 19034275 bambuterol Adrenergics 1322081 Betaxolol Adrenergics 1338005 Bisoprolol Adrenergics 915542 brimonidine Adrenergics 21603320 carbuterol Adrenergics 950370 Carteolol Adrenergics 1346823 carvedilol Adrenergics 19097824 Clenbuterol Adrenergics 1398937 Clonidine Adrenergics 19086622 dapiprazole Adrenergics 19061088 Dexmedetomidine Adrenergics 990009 Dipivefrin Adrenergics 1337720 Dobutamine Adrenergics 1363053 Doxazosin Adrenergics 1143374 Ephedrine Adrenergics 1343916 Epinephrine Adrenergics 19063575 esmolol Adrenergics 19053979 Fenoterol Adrenergics 1196677 formoterol Adrenergics 1366237 Guanabenz Adrenergics 1344965 Guanfacine Adrenergics 19068969 Hexoprenaline Adrenergics 1181809 Isoetharine Adrenergics 21603309 isoprenaline, combinations Adrenergics 1183554 Isoproterenol Adrenergics 1386957 Labetalol Adrenergics 1192218 Levalbuterol Adrenergics 932815 Levobunolol Adrenergics 1123995 metaproterenol Adrenergics 19009365 methoxyphenamine Adrenergics 1305447 Methyldopa Adrenergics 905531 Metipranolol Adrenergics 1307046 Metoprolol Adrenergics 1308368 Midodrine Adrenergics 42873636 mirabegron Adrenergics 1313200 Nadolol Adrenergics 21603310 orciprenaline, combinations Adrenergics 19026274 p-Hydroxyamphetamine Adrenergics 1327978 Penbutolol Adrenergics Brauer R, et al. BMJ Open 2020; 10:e032426. doi: 10.1136/bmjopen-2019-032426 Supplementary material BMJ Open 1335301 Phenoxybenzamine Adrenergics 1335539 Phentolamine Adrenergics 1135766 Phenylephrine Adrenergics 1345858 Pindolol Adrenergics 1125449 pirbuterol Adrenergics 1350489 Prazosin Adrenergics 19028950 Procaterol Adrenergics 1353766 Propranolol Adrenergics 1154332 Pseudoephedrine Adrenergics 19035396 reproterol Adrenergics 1137529 salmeterol Adrenergics 19012925 silodosin Adrenergics 924566 tamsulosin Adrenergics 1341238 Terazosin Adrenergics 1236744 Terbutaline Adrenergics 21603325 terbutaline, combinations Adrenergics 902427 Timolol Adrenergics 778474 tizanidine Adrenergics 21603319 tretoquinol Adrenergics 19043191 tulobuterol Adrenergics 43532539 vilanterol Adrenergics 19029393 aceclofenac Analgesics (inc. NSAIDs) 19029398 acemetacin Analgesics (inc. NSAIDs) 1125315 Acetaminophen Analgesics (inc. NSAIDs) 21603946 alclofenac Analgesics (inc. NSAIDs) 19059528 Alfentanil Analgesics (inc. NSAIDs) 19018431 alminoprofen Analgesics (inc. NSAIDs) 1103552 almotriptan Analgesics (inc. NSAIDs) 19018432 aloxiprin Analgesics (inc. NSAIDs) aminophenazone, combinations excl. 21604337 psycholeptics Analgesics (inc. NSAIDs) aminophenazone, combinations with 21604341 psycholeptics Analgesics (inc. NSAIDs) 19125628 Aminopyrine Analgesics (inc. NSAIDs) 1036059 Antipyrine Analgesics (inc. NSAIDs) 19136654 Apazone Analgesics (inc. NSAIDs) 1112807 Aspirin Analgesics (inc. NSAIDs) 40254364 avocado and soyabean oil, unsaponifiables Analgesics (inc. NSAIDs) 19016435 benorilate Analgesics (inc. NSAIDs) 21603972 benoxaprofen Analgesics (inc. NSAIDs) 19019620 Benzydamine Analgesics (inc. NSAIDs) 21604279 bezitramide Analgesics (inc. NSAIDs) 1139179 bromfenac Analgesics (inc. NSAIDs) 21604346 bucetin Analgesics (inc. NSAIDs) 21604350 bucetin, combinations excl. psycholeptics Analgesics (inc. NSAIDs) 21604353 bucetin, combinations with psycholeptics Analgesics (inc. NSAIDs) 19032724 Bufexamac Analgesics (inc. NSAIDs) Brauer R, et al. BMJ Open 2020; 10:e032426. doi: 10.1136/bmjopen-2019-032426 Supplementary material BMJ Open 19039703 bumadizone Analgesics (inc. NSAIDs) 1133201 Buprenorphine Analgesics (inc. NSAIDs) 1133732 Butorphanol Analgesics (inc. NSAIDs) 21604363 cannabinoids Analgesics (inc. NSAIDs) 21604318 carbasalate calcium Analgesics (inc. NSAIDs) carbasalate calcium combinations excl. 21604324 psycholeptics Analgesics (inc. NSAIDs) 1118084 celecoxib Analgesics (inc. NSAIDs) 1395573 Chondroitin Sulfates Analgesics (inc. NSAIDs) 19018512 clofezone Analgesics (inc. NSAIDs) 1201620 Codeine Analgesics (inc. NSAIDs) 21604268 codeine, combinations with psycholeptics Analgesics (inc. NSAIDs) 21603980 dexibuprofen Analgesics (inc. NSAIDs) 19056874 Dexketoprofen Analgesics (inc. NSAIDs) 19021940 Dextromoramide Analgesics (inc. NSAIDs) dextropropoxyphene, combinations with 21604282 psycholeptics Analgesics (inc. NSAIDs) 19088393 dezocine Analgesics (inc. NSAIDs) 19088915 diacetylrhein Analgesics (inc. NSAIDs) 21604262 DIAMORPHINE Analgesics (inc. NSAIDs) 1124300 Diclofenac Analgesics (inc. NSAIDs) 21603952 difenpiramide Analgesics (inc. NSAIDs) 1126128 Diflunisal Analgesics (inc. NSAIDs) 1189596 dihydrocodeine Analgesics (inc. NSAIDs) 1126557 Dihydroergotamine Analgesics (inc. NSAIDs) 21604370 dihydroergotamine, combinations Analgesics (inc. NSAIDs) 21604313 dipyrocetyl Analgesics (inc. NSAIDs) 21604323 dipyrocetyl, combinations excl. psycholeptics Analgesics (inc. NSAIDs) 21604328 dipyrocetyl, combinations with psycholeptics Analgesics (inc. NSAIDs) 19056645 droxicam Analgesics (inc. NSAIDs) 1189697 eletriptan Analgesics (inc. NSAIDs) 1145379 Ergotamine Analgesics (inc. NSAIDs) 21604372 ergotamine, combinations with psycholeptics Analgesics (inc. NSAIDs) 19059506 ethenzamide Analgesics (inc. NSAIDs) 21604322 ethenzamide, combinations excl. psycholeptics Analgesics (inc. NSAIDs) 21604327 ethenzamide, combinations with psycholeptics Analgesics (inc. NSAIDs) 1195492 Etodolac Analgesics (inc. NSAIDs) 19011355 etoricoxib Analgesics (inc. NSAIDs) 19095703 fenbufen Analgesics (inc. NSAIDs) 1153928 Fenoprofen Analgesics (inc. NSAIDs) 1154029 Fentanyl Analgesics (inc. NSAIDs) 21603950 fentiazac Analgesics (inc. NSAIDs) 19135796 Feprazone Analgesics (inc. NSAIDs) 21604014 feprazone, combinations Analgesics (inc. NSAIDs) 19054931 floctafenine Analgesics (inc. NSAIDs) 19110711 Flufenamic Acid Analgesics (inc. NSAIDs) 21604374 flumedroxone Analgesics (inc. NSAIDs) Brauer R, et al. BMJ Open 2020; 10:e032426. doi: 10.1136/bmjopen-2019-032426 Supplementary material BMJ Open 21603981 flunoxaprofen Analgesics (inc. NSAIDs) 19064698 flupirtine Analgesics (inc. NSAIDs) 1156378 Flurbiprofen Analgesics (inc. NSAIDs) 19113015 fonazine Analgesics (inc. NSAIDs) 1189458 frovatriptan Analgesics (inc. NSAIDs) 21604356 glafenine Analgesics (inc. NSAIDs) 1360332 Glucosamine Analgesics (inc. NSAIDs) 21604004 glucosaminoglycan polysulfate Analgesics (inc. NSAIDs) 21604317 guacetisal Analgesics (inc. NSAIDs) 1174888 Hydrocodone Analgesics (inc. NSAIDs) 1126658 Hydromorphone Analgesics (inc. NSAIDs) 21604295 hydromorphone and antispasmodics Analgesics (inc. NSAIDs) 1177480 Ibuprofen Analgesics (inc. NSAIDs) 21603979 ibuproxam Analgesics (inc. NSAIDs) 19069104 imidazole-2-hydroxybenzoate Analgesics (inc. NSAIDs) 21603958 indometacin, combinations Analgesics (inc. NSAIDs) 1178663 Indomethacin Analgesics (inc. NSAIDs) 21603976 indoprofen Analgesics (inc. NSAIDs) 19113032 iprazochrome Analgesics (inc. NSAIDs) 19069191 kebuzone Analgesics (inc. NSAIDs) 21604270 ketobemidone Analgesics (inc. NSAIDs) 21604293 ketobemidone and antispasmodics Analgesics (inc. NSAIDs) 1185922 Ketoprofen Analgesics (inc. NSAIDs) 21603985 ketoprofen, combinations Analgesics (inc. NSAIDs) 1136980 Ketorolac Analgesics (inc. NSAIDs) 1189766 Levorphanol Analgesics (inc. NSAIDs) 19071933 lonazolac Analgesics (inc. NSAIDs) 19049709 lornoxicam Analgesics (inc. NSAIDs) 19071936 loxoprofen Analgesics (inc. NSAIDs) 21603997 lumiracoxib Analgesics (inc. NSAIDs) 19125097 Meclofenamic Acid Analgesics (inc. NSAIDs) 19125195 Mefenamic Acid Analgesics (inc. NSAIDs) 1150345 meloxicam Analgesics (inc. NSAIDs) 40254075 meloxicam, combinations Analgesics (inc. NSAIDs) 1102527 Meperidine Analgesics (inc. NSAIDs) 19003010 Meptazinol Analgesics (inc. NSAIDs) metamizole sodium, combinations excl. 21604336 psycholeptics Analgesics (inc. NSAIDs) metamizole sodium, combinations with 21604340 psycholeptics Analgesics (inc. NSAIDs) 1103640 Methadone Analgesics (inc. NSAIDs) 21604280 methadone, combinations excl. psycholeptics Analgesics (inc. NSAIDs) 19005257 Methoxyflurane Analgesics (inc. NSAIDs) 1106740 Methysergide Analgesics (inc. NSAIDs) 19072129 mofebutazone Analgesics (inc. NSAIDs) 19072152 morniflumate Analgesics (inc. NSAIDs) 1110410 Morphine Analgesics (inc. NSAIDs) Brauer R, et al. BMJ Open 2020; 10:e032426. doi: 10.1136/bmjopen-2019-032426 Supplementary material BMJ Open 21604292 morphine and antispasmodics Analgesics (inc. NSAIDs) 19056115 MORPHOLINE SALICYLATE Analgesics (inc. NSAIDs) 1113648 nabumetone Analgesics (inc. NSAIDs) 1114122 Nalbuphine Analgesics (inc. NSAIDs) 40254094 naproxcinod Analgesics (inc. NSAIDs) 1115008 Naproxen Analgesics (inc. NSAIDs) 40254098 naproxen and misoprostol Analgesics (inc. NSAIDs) 1118117 naratriptan Analgesics (inc. NSAIDs) 19015602 Nefopam Analgesics (inc. NSAIDs) 909795 nepafenac Analgesics (inc. NSAIDs) 21604259 nicomorphine Analgesics (inc. NSAIDs) 21604334 nifenazone Analgesics (inc. NSAIDs) 19019023 Niflumic Acid Analgesics (inc. NSAIDs) 19069425 nimesulide Analgesics (inc. NSAIDs) 923829 Opium Analgesics (inc. NSAIDs) 19082874 orgotein Analgesics (inc. NSAIDs) 19003691 oxaceprol Analgesics (inc. NSAIDs) 21603953 oxametacin Analgesics (inc. NSAIDs) 1118045 oxaprozin Analgesics (inc. NSAIDs) 19082880 oxetorone Analgesics (inc. NSAIDs) 1124957 Oxycodone Analgesics (inc. NSAIDs) 1125765 Oxymorphone Analgesics (inc. NSAIDs) 19025925 Oxyphenbutazone Analgesics (inc. NSAIDs) 19129648 Papaveretum
Load more

Recommended publications
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Ontario Drug Benefit Formulary Edition 43
    Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Drug Programs Policy and Strategy Branch Ontario Public Drug Programs Ministry of Health and Long-Term Care Effective February 28, 2018 Visit Formulary Downloads: Edition 43 Table of Contents Part I Introduction ....................................................................................................... I.1 Part II Preamble .......................................................................................................... II.1 Part III-A Benefits List ........................................................................................... III-A.1 Part III-B Off-Formulary Interchangeable Drugs (OFI) ........................................ III-B.1 Part IV Section Currently Not In Use ......................................................................... IV Part V Index of Pharmacologic-Therapeutic Classification .................................... V.1 Part VI-A Facilitated Access - HIV/AIDS .............................................................. VI-A.1 Part VI-B Facilitated Access - Palliative Care ..................................................... VI-B.1 Part VI-C Temporary Facilitated Access - Rheumatology ................................. VI-C.1 Part VII Trillium Drug Program ................................................................................ VII.1 Part VIII Exceptional Access Program (EAP) ........................................................ VIII.1 Part IX-A Nutrition Products ................................................................................
    [Show full text]
  • Acebutolol Hydrochloride Eq 200 Mg Base, Capsule, Oral, 100 0.4612 B Eq 400 Mg Base, Capsule, Oral, 100 0.6713 B
    TRANSMITTAL NO. 37 - FEDERAL UPPER LIMIT DRUG LIST NOVEMBER 20, 2001 The following list of multiple source drugs meets the criteria set forth in 42 CFR 447.332 and Section 1927(e) of the Social Security Act, as amended by OBRA 1993. Payment for multiple source drugs identified and listed below must not exceed, in the aggregate, payment levels determined by applying to each drug entity a reasonable dispensing fee (established by the State and specified in the State plan), plus an amount based on the limit per unit which CMS has determined to be equal to 150 percent applied to the lowest price listed (in package sizes of 100 units, unless otherwise noted) in any of the published compendia of cost information of drugs. The listing is based on data current as of April 2001 from First Data Bank (Blue Book), Medi- Span, and the Red Book. This list does not reference the commonly known brand names. However, the brand names are included in the electronic FUL listing provided to the state agencies. The FUL price list and electronic listing are available at http://www.cms.hhs.gov/Reimbursement/05_FederalUpperLimits.asp. In accordance with current policy, Federal financial participation will not be provided for any drug on the FUL listing for which the FDA has issued a notice of an opportunity for a hearing as a result of the Drug Efficacy Study and Implementation (DESI) program, and which has been found to be a less than effective or is identical, related or similar (IRS) to the DESI drug. The DESI drug is identified by the Food and Drug Administration or reported by the drug manufacturer for purposes of the Medicaid drug rebate program.
    [Show full text]
  • Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease
    International Journal of Molecular Sciences Review Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease Michiel Van Bulck 1,2 , Ana Sierra-Magro 1,2, Jesus Alarcon-Gil 1, Ana Perez-Castillo 1,2 and Jose A. Morales-Garcia 1,2,3,* 1 Instituto de Investigaciones Biomédicas (CSIC-UAM), Arturo Duperier, 4. 28029 Madrid, Spain; [email protected] (M.V.B.); [email protected] (A.S.-M.); [email protected] (J.A.-G.); [email protected] (A.P.-C.) 2 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo, 5, 28031 Madrid, Spain 3 Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain * Correspondence: [email protected] Received: 31 December 2018; Accepted: 3 February 2019; Published: 8 February 2019 Abstract: Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases.
    [Show full text]
  • Role of Thrombin and Thromboxane A2 in Reocclusion Following Coronary
    Proc. Natl. Acad. Sci. USA Vol. 86, pp. 7585-7589, October 1989 Medical Sciences Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator (thrombolytic therapy/coronary thrombosis/platelet activation/reperfusion) DESMOND J. FITZGERALD*I* AND GARRET A. FITZGERALD* Divisions of *Clinical Pharmacology and tCardiology, Vanderbilt University, Nashville, TN 37232 Communicated by Philip Needleman, June 28, 1989 (receivedfor review April 12, 1989) ABSTRACT Reocclusion of the coronary artery occurs against the prothrombinase formed on the platelet surface after thrombolytic therapy of acute myocardlal infarction (13) and the neutralization ofheparin by platelet factor 4 (14) despite routine use of the anticoagulant heparin. However, and thrombospondin (15), proteins released by activated heparin is inhibited by platelet activation, which is greatly platelets. enhanced in this setting. Consequently, it is unclear whether To address the role of thrombin during coronary throm- thrombin induces acute reocclusion. To address this possibility, bolysis, we have examined the effect of a specific thrombin we examined the effect of argatroban {MCI9038, (2R,4R)- inhibitor, argatroban {MCI9038, (2R,4R)-4-methyl-1-[N-(3- 4-methyl-l-[Na-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfo- methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2- nyl)-L-arginyl]-2-piperidinecarboxylic acid}, a specific throm- piperidinecarboxylic acid} on the response to tissue plasmin- bin inhibitor, on the response to tissue-type plasminogen ogen activator (t-PA) in a closed-chest canine model of activator in a dosed-chest canine model of coronary thrombo- coronary thrombosis. MCI9038, an argimine derivative which sis. MCI9038 prolonged the thrombin time and shortened the binds to a hydrophobic pocket close to the active site of time to reperfusion (28 + 2 min vs.
    [Show full text]
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • Stroke Prevention in Chronic Kidney Disease Disclosures
    5/18/2020 Controversies: Stroke Prevention in Chronic Kidney Disease Wei Ling Lau, MD FASN FAHA FACP Assistant Professor, Nephrology University of California, Irvine Visiting Fellow at OptumLabsCOPY Disclosures • Prior or current research funding from NIH, AHA, Sanofi, ZS Pharma, and Hub Therapeutics. • Associate Medical Director for home peritoneal dialysis at Fresenius University Dialysis Center of Orange. • Has beenNOT on Fresenius medical advisory board for Velphoro. • No conflicts of interest relevant to the current talk. Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 1 5/18/2020 Stroke Prevention in CKD • Blood pressure targets • Antiplatelet agents • Statins • Anticoagulation Controversies: Stroke prevention in CKD Wei Ling Lau, MD COPY BP TARGETS Data is limited, as patients with CKD were historically excluded from clinical trials NOT Whelton 2017 ACC/AHA hypertension guidelines [Hypertension 2018] Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 2 5/18/2020 Systolic Blood Pressure Intervention Trial SPRINT: BP lowering to <120 vs <140 mmHg significantly lowered rate of CVD composite primary outcome; no clear effect on stroke Controversies: Stroke prevention in CKD The SPRINT Research Group. N Engl J Med 2015 p2103 Wei Ling Lau, MD COPY SPRINT subgroup analysis: CKD • Patients with CKD stage 3‐4 (eGFR of 20 to <60) comprised 28% of the SPRINT study population • Intensive BP management seemed to provide the same benefits for reduction in the CVD composite primary outcomeNOT – but did not impact stroke Controversies: Stroke prevention in CKD Cheung 2017 J Am Soc Nephrol p2812 Wei Ling Lau, MD DO 3 5/18/2020 The hazard of incident stroke associated with systolic BP (SBP) and chronic kidney disease (CKD)BP using and an unadjusted stroke model risk: that contained J‐shaped dummy variables association for CKD and BP groups (A) and a fully adjusted model that contained dummy variables for CKD and BP grou..
    [Show full text]
  • Modafinil and Modafinil Analogues: Free Radical Mechanism of the Eugeroic and Cognitive Enhancment Effect Clifford Fong
    Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford Fong To cite this version: Clifford Fong. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect. [Research Report] Eigenenergy. 2018. hal-01933737 HAL Id: hal-01933737 https://hal.archives-ouvertes.fr/hal-01933737 Submitted on 24 Nov 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford W. Fong Eigenenergy, Adelaide, South Australia. Keywords: Modafinil, modafinil-like analogues, eugeroic effect, cognitive enhancement, free radicals, quantum mechanics Abbreviations Dopamine DA, dopamine transporter DAT, Dissociative electron transfer or attachment DET, Linear free energy relationship LFER, free energy of water desolvation ΔG desolv,CDS , lipophilicity free energy ΔG lipo,CDS, cavity dispersion solvent structure of the first solvation shell CDS, highest occupied molecular orbital HOMO, lowest unoccupied molecular orbital LUMO, multiple correlation coefficient R 2, the F test of significance, standards errors for the estimate (SEE) and standard errors of the variables SE(ΔG desolCDS ), SE(ΔG lipoCDS ), SE(Dipole Moment), SE (Molecular Volume), transition state TS, reactive oxygen species ROS.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Journal of Pharmaceutical and Biomedical Analysis Stability Of
    Journal of Pharmaceutical and Biomedical Analysis 49 (2009) 519–524 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis journal homepage: www.elsevier.com/locate/jpba Short communication Stability of selected chlorinated thiazide diuretics K. Deventer a,∗, G. Baele b, P. Van Eenoo a, O.J. Pozo a, F.T. Delbeke a a DoCoLab, UGent, Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30, B-9052 Zwijnaarde, Belgium b Department of Applied Mathematics and Computer Science, Krijgslaan 281, S9, B-9000 Gent, Belgium article info abstract Article history: In sports, diuretics are used for two main reasons: to flush previously taken prohibited substances with Received 6 August 2008 forced diuresis and in sports where weight classes are involved to achieve acute weight loss. A com- Received in revised form 5 November 2008 mon property observed for thiazides is hydrolysis in aqueous media resulting in the formation of the Accepted 6 November 2008 degradation product aminobenzenedisulphonamide. This degradation product can be observed for sev- Available online 13 November 2008 eral thiazides. Because there is limited information regarding the effect of pH, temperature and light on the stability of thiazides, these parameters were investigated for chlorothiaizide, hydrochlorothiazide Keywords: and altizide. For all three compounds the degradation product could be detected after incubation at pH Doping ◦ Urine 9.5 for 48 h at 60 C. At lower pH and temperature the degradation product could not be detected for all Diuretics compounds. When samples were exposed to UV-light altizide and hydrochlorothiazide were photode- Thiazides graded to chlorothiazide. When the degradation rate between the different compounds was compared Sports for a given temperature and pH, altizide is the most unstable compound.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]